# US 2012/0231008 A1 · Anti-C5A Binding Moieties with High Blocking Activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0231008 A1
- Document ID: US20120231008A1
- Status: Published application
- Kind: A1
- Application number: 13/512,334
- Filed: 2010-11-26
- Published: 2012-09-13
- Earliest claimed: 2009-11-26
- Assignees: InflaRx GmbH
- Inventors: Renfeng Guo; Niels Christoph Reidemann; Yan Li; Beifen Shen
- Web page: https://patentgrep.com/patent/US20120231008A1

## CPC

- C07K 16/18: against material from animals or humans
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/06: Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/00: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K 14/47: from mammals
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/567: Framework region [FR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to binding moieties that specifically bind to a conformational epitope of C5a, in particular human C5a. Preferred binding moieties are anti-C5a antibodies that bind to this conformational epitope. The binding moieties described herein are useful as active agents in pharmaceutical compositions for the treatment and prevention of various acute and chronic diseases, in particular acute inflammatory diseases, such as the systemic inflammatory response syndrome (SIRS), and different degrees of sepsis including sepsis, severe sepsis, and septic shock.

## Claims

### Claim 1

A binding moiety which binds to a conformational epitope formed by amino acid sequences X1X2ETCEX3RX4 (SEQ ID NO: 18) and X5X6KX7X8X9I, (SEQ ID NO: 19) of C5a,
wherein
X1 is selected from the group consisting of N, H, D, F, K, Y, and T;
X2 is selected from the group consisting of D, L, Y, and H;
X3 is selected from the group consisting of Q, E, and K;
X4 is selected from the group consisting of A, V, and L;
X5 is selected from the group consisting of S, H, P, and N;
X6 is selected from the group consisting of H and N;
X7 is selected from the group consisting of D, N, H, P, and G;
X8 is selected from the group consisting of M, L, I, and V; and
X9 is selected from the group consisting of Q, L, and I:
and wherein said binding moiety is selected from the group consisting of:
(a) antibodies or antigen-binding fragments thereof;
(b) oligonucleotides;
(c) antibody-like proteins: and
(d) peptidomimeties.

### Claim 2 (depends on 1)

The binding moiety or claim 1, wherein the binding moiety binds to at least one amino acid of the amino acid sequence X2ETCEX3R (SEQ ID NO: 20), wherein X2 and X3 are defined as in claim 1.

### Claim 3 (depends on 1)

The binding moiety of claims 1, wherein the binding moiety binds to at least one amino acid of the amino acid sequence X6KX7X8X9 (SEQ ID NO: 21),
wherein X6, X7, X8, and X9 are defined as in claim 1.

### Claim 4 (depends on 1)

The binding moiety of claim 1, wherein the conformational epitope is formed by
(a) amino acid sequences NDETCEQRA (SEQ ID NO: 2) and SHKDMQL (SEQ ID NO: 3) of C5a;
(b) amino acid sequences HDETCEQRA (SEQ ID NO: 22) and SHKDLQL (SEQ ID NO: 23) of C5a;
(c) amino acid sequences DDETCEERA (SEQ ID NO: 24) and SHKNIQL (SEQ ID NO: 25) of C5a;
(d) amino acid sequences DLETCEQRA (SEQ ID NO: 26) and SHKHIQL (SEQ ID NO: 27) of C5a;
(e) amino acid sequences DDETCEQRA (SEQ ID NO: 28) and HHKNMQL (SEQ ID NO: 29) of C5a;
(f) amino acid sequences EYETCEERV (SEQ ID NO: 30) and PHKPVQL (SEQ ID NO: 31) of C5a;
(g) amino acid sequences KYETCEQRV (SEQ ID NO: 32) and HHKGMLL (SEQ ID NO: 33) of C5a;
(h) amino acid sequences YDETCEQRA (SEQ ID NO: 34) and SNKPLQL (SEQ ID NO: 35) of C5a; or
(i) amino acid sequences THETCEKRL (SEQ ID NO: 36) and NHKPVIL (SEQ ID NO: 37) of C5a.

### Claim 5 (depends on 1)

The binding moiety of claim 1, wherein the binding moiety binds to at least one amino acid of an amino acid sequence selected from the group consisting of
(SEQ ID NO: 4)
(a) DETCEQR;
(SEQ ID NO: 38)
(b) DETCEER;
(SEQ ID NO: 39)
(c) LETCEQR;
(SEQ ID NO: 40)
(e) YETCEER;
(SEQ ID NO: 41)
(f) YETCEQR;
and
(SEQ ID NO: 42)
(g) HETCEKR.

### Claim 6 (depends on 1)

The binding moiety of claim 1, wherein the binding moiety binds to at least one amino acid of an amino acid sequence selected from the group consisting of
(SEQ ID NO: 5)
(a) HKDMQ;
(SEQ ID NO: 43)
(b) HKDLQ;
(SEQ ID NO: 44)
(c) HKNIQ;
(SEQ ID NO: 45)
(d) HKHIQ;
(SEQ ID NO: 46)
(e) HKNMQ;
(SEQ ID NO: 47)
(f) HKPVQ;
(SEQ ID NO: 48)
(g) HKGML;
(SEQ ID NO: 49)
(h) NKPLQ;
and
(SEQ ID NO: 50)
(i) HKPVI.

### Claim 7 (depends on 1)

The binding moiety of claim 1, wherein said binding moiety exhibits one or more of the following properties:
said binding moiety has a binding constant to C5a with a Kd value of 10 nM or less;
said binding moiety exhibits at least 80% blocking activity for biological effects induced by one molecule C5a;
said binding moiety does not inhibit CH50 activity in human plasma; and
said binding moiety is capable of reducing E. coli induced IL-8 production in human whole blood.

### Claim at position 8

8-11. (canceled)

### Claim 12 (depends on 1)

The binding moiety of claim 1, wherein the binding moiety is an antibody or an antigen-binding fragment thereof, said antibody being selected from the group consisting of polyclonal antibodies, monoclonal antibodies, chimeric antibodies, humanized antibodies, and human antibodies.

### Claim 13 (depends on 1)

The binding moiety of claim 1, wherein the binding moiety is an antigen-binding fragment of an antibody, said fragment being selected from the group consisting of Fab fragments, Fab′ fragment, F(ab′)2 fragments, Fd fragments, Fv fragments, disulfide-linked Fvs (dsFv), single domain antibodies and single chain Fv (scFv) antibodies.

### Claim 14

An antibody or an antigen-binding fragment thereof comprising:
(i) a heavy chain CDR3 sequence as set forth in SEQ ID NO: 6; or
(ii) a heavy chain CDR3 sequence as set forth in SEQ ID NO: 7;
wherein the heavy chain CDR3 sequence optionally comprises 1, 2 or 3 amino acid exchanges, 1, 2, or 3 amino acid deletions and/or 1, 2, or 3 amino acid additions, further comprising at least one of the following sequences:
(i) a heavy chain CDR2 sequence according to SEQ ID NO: 10;
(ii) a heavy chain CDR2 sequence according to SEQ ID NO: 11;
(iii) a light chain CDR2 sequence according to SEQ ID NO: 12;
(iv) a light chain CDR2 sequence according to SEQ ID NO: 13;
(v) a heavy chain CDR1 sequence according to SEQ ID NO: 14;
(vi) a heavy chain CDR1 sequence according to SEQ ID NO: 15;
(vii) a light chain CDR1 sequence according to SEQ ID NO: 16; or
(viii) a light chain CDR1 sequence according to SEQ ID NO: 17;
wherein the heavy chain CDR2 sequence optionally comprises 1, 2 or 3 amino acid exchanges, 1, 2, or 3 amino acid deletions and/or 1, 2, or 3 amino acid additions;
wherein the light chain CDR2 sequence optionally comprises 1, 2 or 3 amino acid exchanges, 1, 2, or 3 amino acid deletions and/or 1, 2, or 3 amino acid additions;
wherein the heavy chain CDR1 sequence optionally comprises 1, 2 or 3 amino acid exchanges, 1, 2, or 3 amino acid deletions and/or 1, 2, or 3 amino acid additions;_, and
wherein the light chain CDR1 sequence optionally comprises 1, 2 or 3 amino acid exchanges. 1, 2, or 3 amino acid deletions and/or 1, 2, or 3 amino acid additions.

### Claim 15 (depends on 14)

The antibody or fragment thereof according to claim 14, further comprising:
(i) a light chain CDR3 sequence as set forth in SEQ ID NO: 8; or
(ii) a light chain CDR3 sequence as set forth in SEQ ID NO: 9;
wherein the light chain CDR3 sequence optionally comprises 1, 2 or 3 amino acid exchanges, 1, 2, or 3 amino acid deletions and/or 1, 2, or 3 amino acid additions.

### Claim 16

An antibody or an antigen-binding fragment thereof comprising:
(i) a light chain CDR3 sequence as set forth in SEQ ID NO: 8; or
(ii) a light chain CDR3 sequence as set forth in SEQ ID NO: 9;
wherein the light chain CDR3 sequence optionally comprises 1, 2 or 3 amino acid exchanges, 1, 2, or 3 amino acid deletions and/or 1, 2, or 3 amino acid additions.

### Claim 17 (depends on 16)

The antibody or fragment thereof according to claim 16, further comprising at least one of the following sequences:
(i) a heavy chain CDR2 sequence according to SEQ ID NO: 10;
(ii) a heavy chain CDR2 sequence according to SEQ ID NO: 11;
(iii) a light chain CDR2 sequence according to SEQ ID NO: 12;
(iv) a light chain CDR2 sequence according to SEQ ID NO: 13;
(v) a heavy chain CDR1 sequence according to SEQ ID NO: 14;
(vi) a heavy chain CDR1 sequence according to SEQ ID NO: 15;
(vii) a light chain CDR1 sequence according to SEQ ID NO: 16; or
(viii) a light chain CDR1 sequence according to SEQ ID NO: 17;
wherein the heavy chain CDR2 sequence optionally comprises 1, 2 or 3 amino acid exchanges, 1, 2, or 3 amino acid deletions and/or 1, 2, or 3 amino acid additions;
wherein the light chain CDR2 sequence optionally comprises 1, 2 or 3 amino acid exchanges, 1, 2, or 3 amino acid deletions and/or 1, 2, or 3 amino acid additions;
wherein the heavy chain CDR1 sequence optionally comprises 1, 2 or 3 amino acid exchanges, 1, 2, or 3 amino acid deletions and/or 1, 2, or 3 amino acid additions; and
wherein the light chain CDR1 sequence optionally comprises 1, 2 or 3 amino acid exchanges, 1, 2, or 3 amino acid deletions and/or 1, 2, or 3 amino acid additions.

### Claim 18

An antibody or an antigen-binding fragment thereof comprising a set of heavy chain CDR3, heavy chain CDR2, and heavy chain CDR1 sequences selected from one of the following sets:
(i) a heavy chain CDR3 sequence according to SEQ ID NO: 6, a heavy chain CDR2 sequence according to SEQ ID NO: 10, and a heavy chain CDR1 sequence according to SEQ ID NO: 14;
(ii) a heavy chain CDR3 sequence according to SEQ ID NO: 6, a heavy chain CDR2 sequence according to SEQ ID NO: 10, and a heavy chain CDR1 sequence according to SEQ ID NO: 15;
(iii) a heavy chain CDR3 sequence according to SEQ ID NO: 6, a heavy chain CDR2 sequence according to SEQ ID NO: 11, and a heavy chain CDR1 sequence according to SEQ ID NO: 14;
(iv) a heavy chain CDR3 sequence according to SEQ ID NO: 6, a heavy chain CDR2 sequence according to SEQ ID NO: 11, and a heavy chain CDR1 sequence according to SEQ ID NO: 15;
(v) a heavy chain CDR3 sequence according to SEQ ID NO: 7, a heavy chain CDR2 sequence according to SEQ ID NO: 10, and a heavy chain CDR1 sequence according to SEQ ID NO: 14;
(vi) a heavy chain CDR3 sequence according to SEQ ID NO: 7, a heavy chain CDR2 sequence according to SEQ ID NO: 10, and a heavy chain CDR1 sequence according to SEQ ID NO: 15;
(vii) a heavy chain CDR3 sequence according to SEQ ID NO: 7, a heavy chain CDR2 sequence according to SEQ ID NO: 11, and a heavy chain CDR1 sequence according to SEQ ID NO: 14; and
(viii) a heavy chain CDR3 sequence according to SEQ ID NO: 7, a heavy chain CDR2 sequence according to SEQ ID NO: 11, and a heavy chain CDR1 sequence according to SEQ ID NO: 15;
wherein each heavy chain CDR3 sequence optionally comprises 1, 2 or 3 amino acid exchanges, 1, 2, or 3 amino acid deletions and/or 1, 2, or 3 amino acid additions;
wherein each heavy chain CDR2 sequence optionally comprises 1, 2 or 3 amino acid exchanges. 1, 2, or 3 amino acid deletions and/or 1, 2, or 3 amino acid additions; and
wherein each heavy chain CDR1 sequence optionally comprises 1, 2 or 3 amino acid exchanges, 1, 2, or 3 amino acid deletions and/or 1, 2, or 3 amino acid additions.

### Claim 19

An antibody or an antigen-binding fragment thereof comprising a set of light chain CDR3, light chain CDR2, and light chain CDR1 sequences selected from one of the following sets:
(i) a light chain CDR3 sequence according to SEQ ID NO: 8, a light chain CDR2 sequence according to SEQ ID NO: 12, and a light chain CDR1 sequence according to SEQ ID NO: 16;
(ii) a light chain CDR3 sequence according to SEQ ID NO: 8, a light chain CDR2 sequence according to SEQ ID NO: 12, and a light chain CDR1 sequence according to SEQ ID NO: 17;
(iii) a light chain CDR3 sequence according to SEQ ID NO: 9, a light chain CDR2 sequence according to SEQ ID NO: 12, and a light chain CDR1 sequence according to SEQ ID NO: 16; and
(iv) a light chain CDR3 sequence according to SEQ ID NO: 9, a light chain CDR2 sequence according to SEQ ID NO: 12, and a light chain CDR1 sequence according to SEQ ID NO: 17;
wherein each light chain CDR3 sequence optionally comprises 1, 2 or 3 amino acid exchanges, 1, 2, or 3 amino acid deletions and/or 1, 2, or 3 amino acid additions;
wherein each light chain CDR2 sequence optionally comprises 1, 2 or 3 amino acid exchanges, 1, 2, or 3 amino acid deletions and/or 1, 2, or 3 amino acid additions; and
wherein each light chain CDR1 sequence optionally comprises 1, 2 or 3 amino acid exchanges, 1, 2, or 3 amino acid deletions and/or 1, 2, or 3 amino acid additions.

### Claim 20 (depends on 1)

A pharmaceutical composition comprising
(a) the binding moiety according to claim 1 or
(b) an antibody or an antigen-binding fragment thereof comprising:
(i) a heavy chain CDR3 sequence as set forth in SEQ NO: 6; or
(ii) a heavy chain CDR3 sequence as set forth in SEQ ID NO: 7;
wherein the heavy chain CDR3 sequence optionally comprises 1, 2 or 3 amino acid exchanges, 1, 2 or 3 amino acid deletions and/or 1, 2, or 3 amino acid additions, further comprising at least one of the following sequences:
(i) a heavy chain CDR2 sequence according to SEQ ID NO: 10;
(ii) a heavy chain CDR2 sequence according to SEQ ID NO: 11;
(iii) a light chain CDR2 sequence according to SEQ ID NO: 12;
(iv) a light chain CDR2 sequence according to SEQ ID NO: 13;
(v) a heavy chain CDR1 sequence according to SEQ ID NO: 14;
(vi) a heavy chain CDR1 sequence according to SEQ ID NO: 15;
(vii) a light chain CDR1 sequence according to SEQ ID NO: 16; or
(viii) a light chain CDR1 sequence according to SEQ ID NO: 17;
wherein the heavy chain CDR2 sequence optionally comprises 1, 2 or 3 amino acid exchanges, 1, 2, or 3 amino acid deletions and/or 1, 2, or 3 amino acid additions;
wherein the light chain CDR2 sequence optionally comprises 1,2 or 3 amino acid exchanges, 1,2, or 3 amino acid deletions and/or 1, 2, or 3 amino acid additions;
wherein the heavy chain CDR1 sequence optionally comprises 1, 2 or 3 amino acid exchanges, 1, 2, or 3 amino acid deletions and/or 1, 2, or 3 amino acid additions; and
wherein the light chain CDR1sequence optionally comprises 1, 2 or 3 amino acid exchanges, 1, 2, or 3 amino acid deletions and/or 1, 2, or 3 amino acid additions,
wherein said pharmaceutical composition further comprises one or more pharmaceutically acceptable carriers, diluents, excipients, fillers, binders, lubricants, glidants, disintegrants, adsorbents, and/or preservatives.

### Claim 21

(canceled)

### Claim 22 (depends on 20)

A method for the prevention and/or treatment of a disease involving acute or chronic inflammation, wherein said method comprises administering, to a subject in need of such prevention and/or treatment, a pharmaceutical composition of claim 20.
